Get the Stockscreener App
0.3633
7.07%
0.024
After Hours:
.36
-0.0033
-0.91%
Mersana Therapeutics Inc stock is traded at $0.3633, with a volume of 2.85M.
It is up +7.07% in the last 24 hours and up +2.80% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$0.3393
Open:
$0.3401
24h Volume:
2.85M
Relative Volume:
1.03
Market Cap:
$45.28M
Revenue:
$36.86M
Net Income/Loss:
$-171.67M
P/E Ratio:
-0.2422
EPS:
-1.5
Net Cash Flow:
$-171.05M
1W Performance:
-4.39%
1M Performance:
+2.80%
6M Performance:
-41.27%
1Y Performance:
-83.18%
1-Day Range:
$0.3393
$0.3777
1-Week Range:
$0.321
$0.39
52-Week Range:
$0.2589
$2.83
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.3633 | 47.36M | 36.86M | -171.67M | -171.05M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Why Mersana Therapeutics Inc. stock attracts strong analyst attentionTrending Stock Alert - Newser
What makes Mersana Therapeutics Inc. stock price move sharplyTop Performing Low Risk Stocks - Newser
How Mersana Therapeutics Inc. stock performs during market volatilityConsistent Win Signals - Newser
Wealth Enhancement Advisory Services LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Mersana Therapeutics Settles Debt with Oxford Finance - TipRanks
Biotech layoff tracker: 18 companies cut 1,300 jobs in Q2 2025 - The Business Journals
Mersana Therapeutics (MRSN) Plunges 5.23% Amid Drug Trial Data - AInvest
94,531 Shares in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Purchased by Pallas Capital Advisors LLC - Defense World
Mersana Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Two Sigma Investments LP Has $302,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Rating of “Buy” by Brokerages - Defense World
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $3 - 富途牛牛
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Acquired by Nuveen Asset Management LLC - Defense World
Bank of America Corp DE Sells 36,084 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Short Interest Up 21.4% in May - Defense World
Millennium Management LLC Increases Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Mersana Therapeutics’ (MRSN) “Outperform” Rating Reaffirmed at William Blair - Defense World
Mersana reports promising Phase 1 ADC trial results By Investing.com - Investing.com South Africa
Mersana reports promising Phase 1 ADC trial results - Investing.com India
Mersana Therapeutics Reports Additional Positive Interim Phase 1 - GuruFocus
Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data - GuruFocus
Mersana Therapeutics (MRSN) Reveals Promising Phase 1 Trial Data for Cancer Treatment | MRSN Stock News - GuruFocus
Mersana Therapeutics Reports Encouraging Interim Phase 1 Results for Emiltatug Ledadotin in B7-H4 High Tumors at ASCO 2025 - Nasdaq
Mersana Therapeutics Reports Additional Positive Interim - GlobeNewswire
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in ... - Eagle-Tribune
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting - Yahoo Finance
Mersana Therapeutics at TD Cowen Summit: Strategic Updates on Oncology Innovations - Investing.com Canada
Deutsche Bank AG Has $1.20 Million Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
D. E. Shaw & Co. Inc. Sells 477,992 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
BNP Paribas Financial Markets Has $516,000 Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Is Now The Time To Buy Mersana Therapeutics Inc (NASDAQ: MRSN) Stock? - Stocksregister
Mersana Therapeutics to Present at Upcoming Investor Conferences - GuruFocus
Mersana Therapeutics Showcases Cancer Drug Pipeline at Goldman Sachs and TD Cowen Healthcare Summits - Stock Titan
Cubist Systematic Strategies LLC Takes Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
William Blair Analysts Lift Earnings Estimates for MRSN - Defense World
Mersana Therapeutics Soars 6.18% on Positive Earnings - AInvest
Q2 EPS Estimate for Mersana Therapeutics Lifted by Analyst - Defense World
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $3.67 Average Price Target from Analysts - Defense World
Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00 - Defense World
Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer - MSN
Mersana Therapeutics (NASDAQ:MRSN) Earns Outperform Rating from Wedbush - Defense World
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates - MSN
MRSN: Truist Securities Raises Price Target for Mersana Therapeutics | MRSN Stock News - GuruFocus
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):